Use of cystic fibrosis inhaled medication before and after elexacaftor/tezacaftor/ivacaftor initiation
Authors:
- Katerina ManikaKMKaterina Manika
- Alexandros KakolyrisAKAlexandros Kakolyris
- Serafeim-Chrysovalantis KotoulasSerafeim-Chrysovalantis Kotoulas
- Elpis HatziagorouElpis Hatziagorou
- 9 May 2023
- journal article
- research article
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 23 (1) , 29-31
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Improved glucose tolerance after initiation of Elexacaftor / Tezacaftor / Ivacaftor in adults with cystic fibrosisJournal of Cystic Fibrosis, 2023
- Pulmonary medication adherence among children and adults with cystic fibrosis: Is there an association with disease severity?Pediatric Pulmonology, 2022
- Research letter: The impact of elexacaftor/tezacaftor/ivacaftor on adherence to nebulized maintenance therapies in people with cystic fibrosisJournal of Cystic Fibrosis, 2022
- Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical TrialAmerican Journal of Respiratory and Critical Care Medicine, 2022
- Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del AlleleNew England Journal of Medicine, 2019
- Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trialThe Lancet, 2019
- ECFS best practice guidelines: the 2018 revisionJournal of Cystic Fibrosis, 2018
- Variation in lung function as a marker of adherence to oral and inhaled medication in cystic fibrosisEuropean Respiratory Journal, 2017
- Cystic Fibrosis Pulmonary GuidelinesAmerican Journal of Respiratory and Critical Care Medicine, 2013
- Longitudinal association between medication adherence and lung health in people with cystic fibrosisJournal of Cystic Fibrosis, 2011